Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen

@article{Prior2019ProgesteroneII,
  title={Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen},
  author={Jerilynn C. Prior},
  journal={The Journal of Clinical Endocrinology \& Metabolism},
  year={2019},
  volume={104},
  pages={1181–1186}
}
  • J. Prior
  • Published 1 April 2019
  • Medicine, Biology
  • The Journal of Clinical Endocrinology & Metabolism
BACKGROUND Although the 2017 Endocrine Society Guidelines for gender dysphoria stipulated that cross-sex hormone therapy (CHT) achieve gonadal steroid levels equivalent to those of a cisperson of the chosen sex, for transgender women (male-to-female gender dysphoria), current gonadal therapy is usually estradiol. Accumulated evidence indicates that normally ovulatory menstrual cycles are necessary for ciswomen's current fertility, as well as for later-life bone and cardiovascular health and the… 
View on Wolters Kluwer
academic.oup.com
30 Citations
Background Citations
5

30 Citations

Citation Type

Citation Type

Reproductive Endocrinology Reference Intervals for Transgender Women on Stable Hormone Therapy.
TLDR
Reference intervals specific to transgender women should be applied when evaluating reproductive endocrine analytes related to reproductive endocrinology in a cohort of healthy gender nonconforming individuals on stable feminizing hormone therapy.
Progesterone in gender-affirming therapy of trans women
TLDR
The present article explores potential clinical implications from the addition of bioidentical progesterone to gender-affirming treatment of trans women and speculates on possible benefits for gender transitioning.
Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
TLDR
Low-dose progesterone was not associated with changes in sleep quality, psychological distress, or breast development over 3 months follow-up, though there was significant inter-individual variability.
Unmasked Testicular Seminoma During Use of Hormonal Transgender Woman Therapy: A Hidden hCG-Secreting Tumor.
TLDR
Testing revealed an elevated serum level of the beta subunit of human chorionic gonadotropin (β-hCG), diagnostic of an hCG-secreting testicular seminoma, as the underlying cause of unexpected T production, illustrating how easily a testicular cancer can remain unnoticed.
A REVIEW OF BREAST DEVELOPMENT IN CISGENDER WOMEN AND IMPLICATIONS FOR TRANSGENDER WOMEN.
  • Tamar Reisman, Zil G Goldstein, J. Safer
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2019
TLDR
The objective of this article is to describe the hormonal pathways required for breast development in cisgender women and to review the current available literature describing breast growth and breast cancer risk in transgender women.
Efficacy of Sex Steroid Therapy without Progestin or GnRH Agonist for Gonadal Suppression in Adult Transgender Patients.
TLDR
T and E2 therapy are usually effective without progestin or GnRHa therapy to suppress gonadal function in transgender patients and should only be initiated in those patients who do not have adequate gonadal suppression on optimized doses of T or E2 alone.
Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
TLDR
The use of hormonal and non-hormonal compounds are suggested, which—based on their mechanism of action—could be used in these cases depending on clients’ requests.
Health considerations for transgender women and remaining unknowns: a narrative review
TLDR
This narrative review aims to comprehensively summarize health considerations for transgender (trans) women and identify TW-related research areas that will provide answers to remaining unknowns surrounding TW’s health.
Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population
TLDR
In short, integrase strand transfer inhibitor–based therapy is not expected to have significant drug interactions with most GAHT and is preferred in most transgender individuals, including those on GAHT, who are considering tailoring ART and GAHT to reduce cardiovascular and other risk factors.
IDEA Group Consensus Statement on Medical Management of Adult Gender Incongruent Individuals Seeking Gender Reaffirmation as Female
TLDR
This consensus statement on medical management provides protocols for the prescribing clinician relating to diagnosis, baseline evaluation and counselling, prescription planning for feminizing hormone therapy and anti-androgen therapy, targets for monitoring hormone therapy, choice of therapy, clinical and biochemical monitoring, recommending sex reaffirmation surgery and peri-operative hormone therapy.
...
...

References

SHOWING 1-10 OF 53 REFERENCES
Oestrogen and anti-androgen therapy for transgender women.
Clinical review: Breast development in trans women receiving cross-sex hormones.
TLDR
The available evidence suggests that breast development is insufficient for the majority of trans women and that type and dosage of hormonal therapy seem not to have an important role on final breast size.
Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy
TLDR
Cross-sex hormone therapy (CSHT), particularly with testosterone, is associated with worsening cardiovascular risk factors in transgender men but not with increases in cardiovascular morbidity or mortality, and the literature regarding the association between CSHT and CVD in transgender adults is summarized.
Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women
TLDR
In this sample of transgender women, lower estrogen doses than those usually prescribed for these subjects were able to adjust the testosterone and estradiol levels to the physiological female range, thus avoiding high estrogen doses and their multiple associated side effects.
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons.
TLDR
Prospective studies suggest interventions related to hormones, surgery, or both are associated with improved psychological functioning and reduction in anxiety and depression in transgender people.
Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study
TLDR
It is shown that, after 1 year of CHT, breast development is modest and occurs primarily in the first 6 months, and no clinical or laboratory parameters were found that predict breast development.
Progesterone for treatment of symptomatic menopausal women
  • J. Prior
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2018
TLDR
Evidence is highlighted that oral micronized progesterone (progesterone) is effective for hot flushes and night sweats, improves sleep and is likely safe in menopausal women (who are more than 1 year since last menstruation).
Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism
The clinical and hormonal response to 12-month therapy with the antiandrogen, spironolactone, in conjunction with near-physiologic doses of female gonadal steroids in 50 transsexual males, is…
Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.
TLDR
MtoF should not be treated with oral ethinyl estradiol, and transdermal estrogens are probably safer than oral estrogens, and pre-existing cardiovascular risks should be taken into consideration when prescribing and choosing the type of estrogens in cross-sex hormone administration (oral vs transDermal).
Endocrine Treatment of Gender‐Dysphoric/Gender‐Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
TLDR
This evidence‐based guideline recommends treating gender‐dysphoric/gender‐incongruent adolescents who have entered puberty at Tanner Stage G2/B2 by suppression with gonadotropin‐releasing hormone agonists and recommends adding gender‐affirming hormones after a multidisciplinary team has confirmed the persistence of gender dysphoria/gender incongruence.
...
...